Newsbot

4 Biotech Stocks Investors Should Watch in 2026

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.

Previewing the 2026 Q2 Earnings Season

The 2026 Q2 earnings season will take the spotlight when the big banks report their results in mid-July. But we will already have seen fiscal May-quarter results from almost two dozen companies by then. What can investors expect?

June Asset Allocation Guidelines

Five different frameworks specify portfolio risk tolerance: from Risky "Max Growth" to Conservative "Income." Choose one that fits you.

Zacks June View on Equity Markets

The significant expansion of ROIC for both Computer-Office Equipment and Electronics from 2020 to today is a classic case of structural tech tailwinds.

ZRS Chart of the Month

Info Tech (7.91) and Industrials (6.39) are very overpriced, based on current valuations. They are +39% and +35% over their medians, respectively.